Jetema Co

Jetema Co Receivables

The Accounts Receivable of Jetema Co (216080.KQ) as of Oct 23, 2026 is 5.31 B KRW. In the previous year, Accounts Receivable was 4.88 B KRW — a change of 8.66% (higher).

Receivables

5.31 BKRW

YoY

8.66%

Last updated:

Accounts Receivable of Jetema Co is 2024 5.31 B KRW. Accounts Receivable of Jetema Co was 2023 4.88 B KRW. It decreases by 8.66% higher compared to the previous year.

The Jetema Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
1.98 B KRW
Jan 1, 2018
3.44 B KRW
Jan 1, 2019
5.12 B KRW
Jan 1, 2020
3.26 B KRW
Jan 1, 2021
2.46 B KRW
Jan 1, 2022
2.21 B KRW
Jan 1, 2023
4.88 B KRW
Jan 1, 2024
5.31 B KRW
The Jetema Co Receivables history
YEARReceivablesYoY
5.31 BKRW+8.66%
4.88 BKRW+121.33%
2.21 BKRW-10.39%
2.46 BKRW-24.41%
3.26 BKRW-36.35%
5.12 BKRW+48.75%
3.44 BKRW+74.00%
1.98 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jetema Co Stock analysis

What does Jetema Co do? Jetema Co., Ltd. generates revenue through the manufacturing and distribution of aesthetic products such as dermal fillers, threads, botulinum toxin, and other medical devices. The company develops and sells hyaluronic acid fillers for facial beauty, medical devices for wrinkle, contour, and volume improvement, and laser equipment for treating leukoplakia, psoriasis, and alopecia areata. Additional products include the lifting medical device epiticons, cosmetic mask packs, and pharmaceutical excaine creams. The primary buyers are medical professionals and clinics seeking cosmetic and dermatological solutions. The company's product portfolio targets the aesthetic and medical device market segments, focusing on non-surgical beauty treatments and skin condition therapies. Jetema Co., Ltd. serves customers in the healthcare sector who require advanced medical devices for cosmetic procedures and dermatological care. The business model centers on direct sales of these specialized medical products to healthcare providers and clinics. Jetema Co., Ltd. operates with a workforce of 187 full-time employees based in Wonju, Gangwon-Do, and has been engaged in the development and manufacturing of hyaluronic acid fillers since its inception. The company's offerings are designed to address specific medical and cosmetic needs, with a focus on facial beauty and skin treatments. Revenue is derived from the sale of these medical devices and related products to healthcare professionals and clinics. Jetema Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jetema Co stock

Accounts Receivable of Jetema Co is 5.31 B KRW in 2024.

Accounts Receivable of Jetema Co changed from 4.88 B KRW to 5.31 B KRW, representing a 8.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Jetema Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Jetema Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Jetema Co

All Key Metrics — Jetema Co